Mucofrin (Acetylcysteine)

Acetylcysteine breaks disulfide bonds in mucus glycoproteins, reducing the viscosity of sputum and facilitating its removal by ciliary action. When given intravenously, it supplies cysteine for glutathione synthesis, helping the liver detoxify the harmful metabolite of acetaminophen.

The dosage of Mucofrin is determined by the prescribing clinician based on the specific indication, patient age, weight, renal and hepatic function, and route of administration. Healthcare professionals follow local guidelines and product labeling to set the appropriate regimen.

Safety data for acetylcysteine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To request Mucofrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Mucofrin’s acetylcysteine is a sulfhydryl‑containing mucolytic that directly cleaves disulfide bonds, offering rapid reduction of mucus viscosity. Compared with agents such as carbocisteine or bromhexine, acetylcysteine also serves as a glutathione precursor, providing an additional benefit in acetaminophen overdose, which other mucolytics lack.

Mucofrin should be stored at 2‑8 °C, protected from light, and kept in its original packaging to maintain stability. Do not freeze the product, and avoid exposing it to excessive heat or direct sunlight. Once removed from refrigeration, use within the time frame indicated on the label.

Mucofrin is supplied as a sterile solution for inhalation via nebulisation or for intravenous infusion. The route, infusion rate, and duration are determined by the treating physician according to the clinical indication and patient tolerance.

Serious adverse reactions include anaphylactoid responses such as severe bronchospasm, hypotension, and rare skin conditions like Stevens‑Johnson syndrome. Intravenous use may also lead to hepatic enzyme elevation or acute renal impairment, especially in patients with pre‑existing organ dysfunction.

Mucofrin is contraindicated in individuals with known hypersensitivity to acetylcysteine or other sulfhydryl‑containing compounds. Caution is advised for patients with severe asthma, uncontrolled cardiovascular disease, or those receiving nitroglycerin, as the combination can precipitate marked hypotension.